Annie Yang1, David Goldin2, Jose Nova2, Jyoti Malhotra3, Joel C Cantor2, Jennifer Tsui2,3,4. 1. New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ. 2. Center for State Health Policy, Rutgers, The State University of New Jersey, New Brunswick, NJ. 3. Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ. 4. School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ.
Abstract
PURPOSE: Racial and ethnic disparities in cancer care near the end of life (EOL) have been recognized, but EOL care experienced by Medicaid beneficiaries is not well understood. We assessed the prevalence of aggressive EOL care and hospice enrollment for Medicaid beneficiaries and determined whether racial and ethnic disparities exist. PATIENTS AND METHODS: We identified Medicaid beneficiaries (age 21-64 years) who were diagnosed from 2011 to 2015 with stage IV breast and colorectal cancer and who died by January 2016 through a New Jersey State Cancer Registry-Medicaid claims linked data set. We measured aggressive EOL care (> 1 hospitalization, > 1 emergency department [ED] visit, any intensive care unit [ICU] admission in the last 30 days of life, and receipt of chemotherapy in the last 14 days of life) and hospice enrollment. Multivariable logistic regression models were used to determine factors associated with aggressive EOL care and hospice enrollment. RESULTS: Of the 349 patients, 217 (62%) received at least one of the following measures of aggressive EOL care: > 1 hospitalization (27%), > 1 ED visit (31%), ICU admission (30%), and chemotherapy (34%). The adjusted odds of receiving any aggressive care were 1.87 times higher (95% CI, 1.08 to 3.26) for non-Hispanic (NH) Black patients compared with NH White patients. Only 39% of patients enrolled in hospice. No significant differences in hospice enrollment were observed by race or ethnicity. CONCLUSION: The majority of Medicaid patients with advanced cancer received aggressive EOL care and were not enrolled in hospice. NH Black patients were more likely to receive aggressive EOL care. Further work to understand processes leading to suboptimal EOL care within Medicaid populations and among racial and ethnic minority groups is warranted.
PURPOSE: Racial and ethnic disparities in cancer care near the end of life (EOL) have been recognized, but EOL care experienced by Medicaid beneficiaries is not well understood. We assessed the prevalence of aggressive EOL care and hospice enrollment for Medicaid beneficiaries and determined whether racial and ethnic disparities exist. PATIENTS AND METHODS: We identified Medicaid beneficiaries (age 21-64 years) who were diagnosed from 2011 to 2015 with stage IV breast and colorectal cancer and who died by January 2016 through a New Jersey State Cancer Registry-Medicaid claims linked data set. We measured aggressive EOL care (> 1 hospitalization, > 1 emergency department [ED] visit, any intensive care unit [ICU] admission in the last 30 days of life, and receipt of chemotherapy in the last 14 days of life) and hospice enrollment. Multivariable logistic regression models were used to determine factors associated with aggressive EOL care and hospice enrollment. RESULTS: Of the 349 patients, 217 (62%) received at least one of the following measures of aggressive EOL care: > 1 hospitalization (27%), > 1 ED visit (31%), ICU admission (30%), and chemotherapy (34%). The adjusted odds of receiving any aggressive care were 1.87 times higher (95% CI, 1.08 to 3.26) for non-Hispanic (NH) Black patients compared with NH White patients. Only 39% of patients enrolled in hospice. No significant differences in hospice enrollment were observed by race or ethnicity. CONCLUSION: The majority of Medicaid patients with advanced cancer received aggressive EOL care and were not enrolled in hospice. NH Black patients were more likely to receive aggressive EOL care. Further work to understand processes leading to suboptimal EOL care within Medicaid populations and among racial and ethnic minority groups is warranted.
Authors: Joan M Teno; Pedro Gozalo; Amal N Trivedi; Jennifer Bunker; Julie Lima; Jessica Ogarek; Vincent Mor Journal: JAMA Date: 2018-07-17 Impact factor: 56.272
Authors: Jonathan Bergman; Christopher S Saigal; Karl A Lorenz; Janet Hanley; David C Miller; John L Gore; Mark S Litwin Journal: Arch Intern Med Date: 2010-10-11
Authors: Jennifer W Mack; Angel Cronin; Nancy L Keating; Nathan Taback; Haiden A Huskamp; Jennifer L Malin; Craig C Earle; Jane C Weeks Journal: J Clin Oncol Date: 2012-11-13 Impact factor: 44.544
Authors: Elizabeth Ward; Michael Halpern; Nicole Schrag; Vilma Cokkinides; Carol DeSantis; Priti Bandi; Rebecca Siegel; Andrew Stewart; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2007-12-20 Impact factor: 508.702
Authors: Katie Fitzgerald Jones; Esther Laury; Justin J Sanders; Lauren T Starr; William E Rosa; Staja Q Booker; Melissa Wachterman; Christopher A Jones; Susan Hickman; Jessica S Merlin; Salimah H Meghani Journal: J Palliat Med Date: 2021-11-16 Impact factor: 2.947
Authors: David Boyce-Fappiano; Kaiping Liao; Christopher Miller; Susan K Peterson; Linda Elting; B Ashleigh Guadagnolo Journal: J Pain Symptom Manage Date: 2021-02-05 Impact factor: 5.576
Authors: Stephanie Deeb; Fumiko L Chino; Lisa C Diamond; Anna Tao; Abraham Aragones; Armin Shahrokni; Divya Yerramilli; Erin F Gillespie; C Jillian Tsai Journal: JAMA Netw Open Date: 2021-09-01
Authors: Karen J Ortiz-Ortiz; Guillermo Tortolero-Luna; Carlos R Torres-Cintrón; Diego E Zavala-Zegarra; Axel Gierbolini-Bermúdez; María R Ramos-Fernández Journal: JCO Oncol Pract Date: 2021-02
Authors: Lauren T Starr; Connie M Ulrich; G Adriana Perez; Subhash Aryal; Paul Junker; Nina R O'Connor; Salimah H Meghani Journal: Am J Hosp Palliat Care Date: 2021-07-28 Impact factor: 2.090